Avicanna is a Canadian commercial-stage biopharmaceutical company established in cannabinoid research, development, and evidence-based products.
In leading global cannabinoid advancements, Avicanna conducts most of its research in Canada at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS Discovery District. The Company actively collaborates with leading Canadian academic and medical institutions.
Medical Cannabis and Wellness Products
CBD Dermacosmetics Consumer Retail Products*
In Development and Registration Stage
Cannabinoid API & Seeds
Medical Cannabis & Wellness Products
Marketed under the RHO Phyto™ brand, or Magisterial Preparations
These medical and wellness products are an advanced line of pharmaceutical-grade cannabis products containing varying ratios of cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”).
The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data.
The advanced formulary is marketed with consumer, patient and medical community education and training. Avicanna’s medical and wellness product portfolio also forms the foundation of the Company’s pharmaceutical pipeline with the contribution of the formulations that form the basis of the products as well as the data generated from sales and participation of the products in real world evidence studies.
CBD Derma-Cosmetic Products
Marketed under the Pura H&W™ or Pura Earth™.
These registered, clinically tested, dermacosmetic products include a portfolio of functional CBD topical products. They include a line of topical products that have been designed to delivery CBD in synergy with other natural ingredients for specific functional skin benefits.
Avicanna pipeline of patent-pending drug candidates.
Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates which are indication-specific and in various stages of clinical development and commercialization.
These cannabinoid-based drug candidates provide solutions for unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna’s first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America.
Cannabis Raw Materials, Seeds & Bulk Formulations
Marketed under the Aureus™ brand, the Company’s raw material business has successfully completed sales to 11 countries.
Aureus offers cannabis dried flower, standardized seeds, full spectrum extracts, and cannabinoid distillates, isolated cannabinoids (CBD, THC, cannabigerol (“CBG”) and other rare cannabinoids), and bulk formulations derived from hemp and cannabis cultivars through its sustainable, economical, and industrial-scale subsidiaries based in Colombia.
Majority of the Aureus products are produced at SMGH, the Company’s majority-owned subsidiary which is also Good Agricultural and Collection Practices (“GACP”) and USDA organic certified.Majority of the Aureus products are produced at SMGH, the Company’s majority-owned subsidiary which is also Good Agricultural and Collection Practices (“GACP”) and USDA organic certified.
Research & Developement
Industry leading scientific platform and intellectual property
Established Research & Development Platform
Setting the Standard in the Cannabinoid Industry with Advanced and Evidence Based Product
R&D headquarters at JLABS @ Toronto, Johnson & Johnson Innovation Centre in the MaRS Discovery District
Drug development pipeline, including sustained release tablets, transdermal patches and nano participle formulations
Commercial stage proprietary products
Canadian Government research grants awarded since 2020
Health Canada cannabis R&D licenses issued to Avicanna and its academic collaborators